StockNews.com Begins Coverage on Fresenius Medical Care (NYSE:FMS)

StockNews.com started coverage on shares of Fresenius Medical Care (NYSE:FMS) in a report published on Sunday morning. The firm issued a strong-buy rating on the stock.

Separately, Truist Financial cut their price target on Fresenius Medical Care from $24.00 to $22.00 and set a hold rating for the company in a report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of Hold and a consensus target price of $22.00.

Fresenius Medical Care Stock Performance

NYSE:FMS opened at $20.82 on Friday. Fresenius Medical Care has a 52-week low of $16.37 and a 52-week high of $22.76. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.09 and a current ratio of 1.46. The firm has a market capitalization of $12.22 billion, a PE ratio of 23.39, a P/E/G ratio of 1.09 and a beta of 0.90. The stock has a 50-day simple moving average of $19.60 and a two-hundred day simple moving average of $19.93.

Fresenius Medical Care (NYSE:FMS) last posted its quarterly earnings results on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.38. The business had revenue of $5.13 billion during the quarter, compared to analyst estimates of $5.28 billion. Fresenius Medical Care had a net margin of 2.72% and a return on equity of 5.48%. Analysts forecast that Fresenius Medical Care will post 1.51 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Assetmark Inc. increased its stake in shares of Fresenius Medical Care by 169.9% in the fourth quarter. Assetmark Inc. now owns 4,178 shares of the company’s stock worth $87,000 after acquiring an additional 2,630 shares during the period. GAMMA Investing LLC increased its position in shares of Fresenius Medical Care by 21.8% during the first quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock valued at $82,000 after acquiring an additional 758 shares during the last quarter. ORG Partners LLC acquired a new stake in shares of Fresenius Medical Care during the first quarter valued at about $110,000. SageView Advisory Group LLC acquired a new stake in shares of Fresenius Medical Care during the first quarter valued at about $127,000. Finally, Signaturefd LLC boosted its stake in shares of Fresenius Medical Care by 8.4% in the second quarter. Signaturefd LLC now owns 8,713 shares of the company’s stock valued at $166,000 after purchasing an additional 672 shares during the period. Institutional investors own 8.25% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.